Avastin's Stumble Again At NICE Underscores Importance Of Overall Survival Data

NICE rejection of Roche's Avastin comes a week ahead of target dates for U.S. and EU decisions on possibly withdrawing the indication, but still offers instructive lessons for working with technology assessment groups.